samedan logo
 
 
spacer
home > ebr > spring 2003 > capital markets slowdown triggers pharma micro-deals in 2002
PUBLICATIONS
European BioPharmaceutical Review

Capital Markets Slowdown Triggers Pharma Micro-Deals in 2002

In 2002 the ability of companies to raise funds on either the public or private markets was greatly restricted, triggering a substantial reduction in the average value of M&A deals in the pharma sector.

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Neal Ransome, Partner at PricewaterhouseCoopers

Neal Ransome is the European leader of PricewaterhouseCoopers' Pharmaceuticals and Healthcare Corporate Finance team. He has over 10 years' experience of corporate finance transactions, and has been focusing on the pharma and health care sectors since 1997. Neal's clients in the sector have included large pharma companies such as GlaxoSmithKline and Aventis, emerging companies such as Powderject and a wide range of smaller clients in the health care and biotech sectors.

Neal has also acted for a large number of private equity clients in the sector, including 3i, Warburg Pincus and Phoenix. The European team which he leads comprises approximately 20 professional staff, located in all key financial centres, and combines corporate finance experts with recruits from the industry.

spacer
Neal Ransome
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Paediatric Clinical Trials

19-20 January 2009, Copthorne Tara Hotel, London, UK


More info >>

 
News and Press Releases

Stora Enso with DDSi is Winner of HCPC-Europe Packaging Award 2008

 11th November 2008
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement